Physician profile
Roman Polishchuk
NPI 1467715839
$380.17
in general payments reported to CMS, 2019-2025
10 companies · $18.37 in 2025
The $18.37 reported for 2025 was less than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $230 · 2020: $42.90 · 2021: $30.92 · 2022: $42.19 · 2024: $15.74 · 2025: $18.37.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $34.11.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $34.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $133.29 | 2019-2020 | |
| Aerie Pharmaceuticals, INC. | $99.88 | 2019 | |
| Allergan, INC. | $34.45 | 2020-2021 | |
| Abbvie INC. | $23.07 | 2022 | |
| Dompe US, INC. | $19.12 | 2022 | |
| Bausch & Lomb Americas INC. | $18.37 | 2025 | Xiidra |
| Eyevance Pharmaceuticals LLC | $17.79 | 2019 | |
| Kala Pharmaceuticals, INC. | $16.46 | 2021 | |
| Alcon Vision LLC | $15.74 | 2024 | Rocklatan |
| Travere Therapeutics, INC. | $2.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roman Polishchuk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.